Presentations by Stanley Jordan

• Tue-15 from 10:30 - 11:15 in room Channel 11
  Kidney Transplantation: Antibody-mediated rejection and composite end points
  Clazakizumab (Anti-IL-6 Monoclonal) treatment of patients with chronic & active antibody-mediated rejection post-kidney transplantation (NCT03380377)
• Wed-16 from 10:30 - 11:15 in room Channel 6
  Kidney Transplantation: Desensitization and other complications
  Clazakizumab (anti-IL-6) induces FoxP3+ Tregs in highly HLA sensitized patients receiving HLAi kidney transplantation (NCT03380962)
• Wed-16 from 13:00 - 14:00 in room Channel 1
  Hansa - Current & future approaches in kidney transplant of highly sensitised patient
  Emerging therapies & future approaches
• Sun-13 from 22:00 - 23:00 in room Channel 1
  CareDx Virtual Meetings
  Clinical utility of non-invasive molecular biomarkers: Understanding molecular injury